Gilde Healthcare Services invests in nursing homes - Gilde Healthcare

Gilde Healthcare Services invests in nursing homes

25 oktober 2010

Utrecht, The Netherlands – Gilde Healthcare Services (Gilde), a growth capital fund specialised in Healthcare Services, has acquired a significant minority stake in elderly care provider Stepping Stones Home & Care (Stepping Stones) of the Netherlands to fund further growth of the company.

Stepping Stones operates a chain of nursing homes providing care for elderly with Alzheimer’s disease and related conditions that need continuous support. The nursing homes offer a safe, protected and continuous care environment with affordable services tailored to the needs of residents (www.steppingstonesbv.nl).

Stepping Stones founding managers Arthur Scherpenzeel and Christiaan Sap commented:

“We are thrilled with the investment from Gilde. This investment not only enables us to expand the number of locations but we will also benefit from Gilde’s hands-on approach and healthcare expertise.

Jasper van Gorp, Partner of the Gilde Healthcare Services fund said:

“We were impressed by Stepping Stones’ ability to provide a very high quality yet affordable care home service. We believe that there is a considerable need for this type of service which can co-exist alongside care provided by the public sector in the Netherlands. This investment is aligned perfectly with our investment focus on high growth healthcare services companies.

Gilde Healthcare invests alongside Capital A in Tromp Medical to accelerate international growth in the medical imaging market

Tromp Medical, Europe’s largest independent medical imaging sales and service organization, has attracted Gilde Healthcare as new investor to drive further growth in the medical imaging market. Headquartered in the Netherlands, Tromp Medical specializes in...
16 december 2024

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first...
12 december 2024

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital...
11 december 2024